
|Videos|May 11, 2020
Update on HER2-Targeted Therapy in Early Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, discusses newer approaches to managing early stages of HER2+ breast cancer in both the neoadjuvant and adjuvant spaces.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tinostamustine Orphan Drug Designation for Malignant Gliomas
2
A 25-Year Snapshot of Survival With Metastatic Breast Cancer and Brain Metastases
3
FDA Fast Tracks Bispecific ADC AVZO-1418 for EGFR-Mutated Pretreated NSCLC
4
Behind the FDA’s Elimination of REMS Program for CAR T-Cell Therapies
5





































